Finance

Lists
Why is 3696 up 3,88%?
Dive Deeper
3696:HKG
Insilico Medicine Cayman TopCo
39,10 HK$
+3,88%
(+1,46) 1D
16 հոկ, 16:08:14 GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 3696...
Open
39,16 HK$
High
40,28 HK$
Low
38,12 HK$
Mkt. cap
22,88 մլրդ
Avg. vol.
15,66 մլն
Volume
15,71 մլն
52-wk high
80,90 HK$
52-wk low
29,98 HK$
EPS
-4,20 HK$
Shares outstanding
557,42 մլն
No. of employees
333
Open
39,16 HK$
High
40,28 HK$
Low
38,12 HK$
Mkt. cap
22,88 մլրդ
Avg. vol.
15,66 մլն
Volume
15,71 մլն
52-wk high
80,90 HK$
52-wk low
29,98 HK$
EPS
-4,20 HK$
Shares outstanding
557,42 մլն
No. of employees
333
News stories
From web sources and news partners
Profile
Insilico Medicine is a biotechnology company headquartered in Boston, Massachusetts, with additional facilities in Pak Shek Kok, Hong Kong in Hong Kong Science Park near the Chinese University of Hong Kong, and in New York, at The Cure by Deerfield. The company applies genomics, big data analysis, and deep learning for in silico drug discovery. Wikipedia
About Insilico Medicine Cayman TopCo
CEOFeng Ren | Alex Zhavoronkov
Employees333
Founded2014
Headquarters-
Sector-
Last report
26 օգս, 2026 թ.
Fiscal period
Q2 2026
- / -
Revenue / Est. (USD)
53,15 մլն / -
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 թ. սեպ
2025 թ. դեկ
2026 թ. մրտ
2026 թ. հնս
Revenue
14,39 մլն
14,39 մլն
53,15 մլն
53,15 մլն
Cost of goods sold
2,98 մլն
2,98 մլն
5,17 մլն
5,17 մլն
Cost of revenue
2,98 մլն
2,98 մլն
5,17 մլն
5,17 մլն
Research and development expenses
22,90 մլն
22,90 մլն
24,66 մլն
24,66 մլն
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
7,05 մլն
7,05 մլն
9,47 մլն
9,47 մլն
Operating expense
30,23 մլն
30,23 մլն
33,85 մլն
33,85 մլն
Total operating expenses
33,20 մլն
33,20 մլն
39,02 մլն
39,02 մլն
Operating income
-18,81 մլն
-18,81 մլն
14,14 մլն
14,14 մլն
Other non operating income
-149,82 մլն
-149,82 մլն
1,50 հզր
1,50 հզր
EBT including unusual items
-166,54 մլն
-166,54 մլն
17,91 մլն
17,91 մլն
EBT excluding unusual items
-167,61 մլն
-167,61 մլն
16,57 մլն
16,57 մլն
Income tax expense
9,50 հզր
9,50 հզր
139,50 հզր
139,50 հզր
Effective tax rate
-0,01%
-0,01%
0,78%
0,78%
Other operating expenses
-
-
-
-
Net income
-166,55 մլն
-166,55 մլն
17,77 մլն
17,77 մլն
Net profit margin
-1 157,28%
-1 157,28%
33,43%
33,43%
Earnings per share
-
-
-
-
Interest and investment income
1,29 մլն
1,29 մլն
3,89 մլն
3,89 մլն
Interest expense
-56,00 հզր
-56,00 հզր
-83,00 հզր
-83,00 հզր
Net interest expenses
1,24 մլն
1,24 մլն
3,81 մլն
3,81 մլն
Depreciation and amortization charges
-
-
-
-
EBITDA
-18,08 մլն
-18,08 մլն
14,89 մլն
14,89 մլն
Gain or loss from assets sale
63,50 հզր
63,50 հզր
-
-
AI content may include mistakes. Learn more
Google Apps